12 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $638M | -$183M | 0.0% | -26.1% | -$94M | $188M | $323M |
| 2024 | $386M | -$287M | 0.0% | -72.7% | -$129M | $181M | $315M |
| 2023 | $271M | -$239M | 0.0% | -85.7% | -$146M | $178M | $386M |
| 2022 | $50M | -$187M | 89.6% | -359.3% | -$117M | $94M | $201M |
| 2021 | — | -$130M | — | — | -$109M | $49M | $86M |
| 2020 | — | -$103M | — | — | -$79M | $48M | $184M |
| 2019 | — | -$68M | — | — | -$46M | $20M | $220M |
| 2018 | — | -$31M | — | — | -$30M | $7M | — |
| 2017 | — | -$29M | — | — | -$26M | $10M | — |
| 2016 | — | -$27M | — | — | -$21M | $10M | — |
| 2015 | — | -$12M | — | — | -$7M | — | — |
| 2014 | — | -$6M | — | — | — | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $191M | -$65M | 0.0% | -33.1% | -$21M | $188M | $305M |
| Dec '25 | $196M | -$29M | 0.0% | -13.8% | -$19M | $188M | $323M |
| Sep '25 | $171M | -$47M | 0.0% | -27.0% | $988000 | $188M | $325M |
| Jun '25 | $150M | -$48M | 0.0% | -24.5% | -$32M | $188M | $303M |
| Mar '25 | $121M | -$59M | 0.0% | -46.9% | -$44M | $181M | $301M |
| Dec '24 | $119M | -$75M | 0.0% | -61.1% | -$26M | $181M | $315M |
| Sep '24 | $105M | -$65M | 0.0% | -59.8% | -$19M | $180M | $327M |
| Jun '24 | $87M | -$79M | 0.0% | -89.5% | -$30M | $179M | $316M |
| Mar '24 | $75M | -$68M | 0.0% | -89.7% | -$54M | $179M | $331M |
| Dec '23 | $72M | -$99M | 0.0% | -137.4% | -$30M | $178M | $386M |
| Sep '23 | $58M | -$62M | 0.0% | -107.5% | -$54M | $177M | $417M |
| Jun '23 | $47M | -$67M | 0.0% | -139.3% | -$55M | $177M | $437M |
| Mar '23 | $95M | -$11M | 0.0% | -6.7% | -$6M | $148M | $247M |
| Dec '22 | $24M | -$61M | 90.6% | -245.9% | -$28M | $94M | $201M |
| Sep '22 | $17M | -$45M | 88.7% | -251.8% | -$23M | $94M | $228M |
| Jun '22 | $9M | -$41M | 88.7% | -444.2% | -$34M | $93M | $73M |
| Mar '22 | — | -$40M | — | — | -$33M | $49M | $85M |
| Dec '21 | — | -$34M | — | — | -$29M | $49M | $86M |
| Sep '21 | — | -$35M | — | — | -$27M | $49M | $115M |
| Jun '21 | — | -$32M | — | — | -$25M | $49M | $141M |
How the market has priced AXSM against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Axsome Therapeutics, Inc.'s revenue has grown 133.7% per year. These are computed facts, not advice.
As of FY2025, Axsome Therapeutics, Inc. reported $188M of total debt against $323M of cash; operating income covered interest expense 10×.
In FY2025, gross margin was —, operating margin -26.1%, and net margin -28.7%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.